Acute myeloid leukemia

Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024

Retrieved on: 
Thursday, February 15, 2024

WILMINGTON, Del., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the fiscal year ended December 31, 2023, and outlined key objectives for 2024.   

Key Points: 
  • “Our partnership with AbCellera represents a strategic step to expand our pipeline, based on our core competencies in medicinal chemistry, cancer biology and clinical development.
  • A second cohort of patients with AML is expected to initiate in the first half of 2024.
  • Under the terms of the agreement, Prelude and AbCellera will jointly discover, develop, and commercialize products emerging from the collaboration.
  • The decrease in general and administrative expenses was primarily due to our continued management of general and administrative expenses.

OnKure Announces the Appointment of Samuel Agresta, M.D., as Chief Medical Officer

Retrieved on: 
Thursday, February 15, 2024

BOULDER, Colo., Feb. 15, 2024 (GLOBE NEWSWIRE) -- OnKure, Inc. today announced the appointment of Samuel Agresta, M.D., M.P.H.

Key Points: 
  • BOULDER, Colo., Feb. 15, 2024 (GLOBE NEWSWIRE) -- OnKure, Inc. today announced the appointment of Samuel Agresta, M.D., M.P.H.
  • as Chief Medical Officer.
  • “Sam’s leadership experience and expertise in oncology drug development will be invaluable as we advance our portfolio,” said Nick Saccomano, Ph.D., Chief Executive Officer of OnKure.
  • Dr. Agresta also served as a Director and Chief Medical Officer at Infinity Pharmaceuticals, Inc. where he was responsible for the Phase 1 and 2 developments of the PI3Ky inhibitor, IPI-549.

TCBP Provides Shareholder Update and Highlights Upcoming Milestones

Retrieved on: 
Wednesday, February 14, 2024

"The previous year was a time of significant operational achievement for TC BioPharm," said Bryan Kobel, Chief Executive Officer.

Key Points: 
  • "The previous year was a time of significant operational achievement for TC BioPharm," said Bryan Kobel, Chief Executive Officer.
  • We look forward/expect to continue this pattern of execution in 2024 and hitting our key milestones as laid out."
  • Entered into a collaboration agreement with Queen Mary University of London (QMUL) to expand the platform into non-oncology indications.
  • Management is focused on leveraging existing strategic relationships in order to execute partnerships and or collaborations in combination with TCB-008.

TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR

Retrieved on: 
Wednesday, February 14, 2024

WALTHAM, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the Company will host a virtual key opinion leader (KOL) event to discuss updated results from its Phase 1 heme malignancies study and highlights from its oral presentation at the 2024 Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT®) and the Center for International Blood and Marrow Transplant Research (CIBMTR®) on Monday, February 26, 2024, at 8:00 a.m. ET.

Key Points: 
  • ET.
  • The event will provide an in-depth review of the oral presentation related to TScan’s ongoing Phase 1 multi-arm clinical trial evaluating TSC-100 and TSC-101, which are designed to treat residual disease and prevent relapse following hematopoietic cell transplantation (HCT) in patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or acute lymphocytic leukemia (ALL) ( NCT05473910 ).
  • The Company will also discuss the potential implications of initial data from a large prospective clinical trial assessing the relationship between donor chimerism and risk of relapse.
  • Shrikanta Chattopadhyay, M.D., M.M.Sc., Senior Vice President of Medical and Translational Medicine, TScan Therapeutics

MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights

Retrieved on: 
Tuesday, February 13, 2024

As of December 31, 2023, MEI had $59.5 million in cash, cash equivalents, and short-term investments with no outstanding debt.

Key Points: 
  • As of December 31, 2023, MEI had $59.5 million in cash, cash equivalents, and short-term investments with no outstanding debt.
  • Research and development expenses decreased by $11.4 million to $3.9 million for the quarter ended December 31, 2023, compared to $15.3 million for the quarter ended December 31, 2022.
  • General and administrative expenses decreased by $0.5 million to $8.0 million for the quarter ended December 31, 2023, compared to $8.5 million for the quarter ended December 31, 2022.
  • MEI recognized no revenue for the quarter ended December 31, 2023, compared to $32.7 million for the quarter ended December 31, 2022.

Auron Selects First Development Candidate for its Portfolio of Next-Generation Targeted Cancer Treatments from its Novel AURIGIN™ Platform

Retrieved on: 
Thursday, February 8, 2024

NEWTON, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and treating disrupted cell states of cancer, today announced the nomination of its first development candidate, AUTX-703. Using its proprietary AURIGIN platform, Auron identified a key driver of tumor cell plasticity and discovered AUTX-703, a potent, selective, orally bioavailable small molecule degrader of that target. AUTX-703 is being developed for the treatment of patients with small cell lung cancer (SCLC), neuroendocrine prostate cancer (NEPC), and acute myeloid leukemia (AML).

Key Points: 
  • AUTX-703 is being developed for the treatment of patients with small cell lung cancer (SCLC), neuroendocrine prostate cancer (NEPC), and acute myeloid leukemia (AML).
  • In cancer, genetic or pathway alterations hijack normal development pathways to promote tumorigenesis by pushing cancer cells into a more plastic, proliferative cell state.
  • “One of the most significant challenges to effectively treating cancer is the ability of cancer cells to change their cellular identity.
  • The selection of AUTX-703 is an important step toward broadly applying our AURIGIN platform for the development of a range of next-generation targeted cancer therapies.”

Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive Officer

Retrieved on: 
Wednesday, February 7, 2024

FOSTER CITY, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Amy Burroughs as chief executive officer (CEO), effective immediately.

Key Points: 
  • FOSTER CITY, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Amy Burroughs as chief executive officer (CEO), effective immediately.
  • Ms. Burroughs will also join the Terns board of directors.
  • “We are pleased to welcome Amy to the Terns team to lead the company in its next stage of growth,” said David Fellows, chairman of the board of directors.
  • Ms. Burroughs earned an M.B.A. from Harvard Business School, where she graduated as a Baker Scholar, and a B.A.

Delta-Fly Pharma Inc.: Abstracts submission for Phase I Clinical Trial of DFP-14927 to 2024 ASCO annual meeting

Retrieved on: 
Wednesday, February 7, 2024

in 2024, we are excited to share our latest development status.

Key Points: 
  • in 2024, we are excited to share our latest development status.
  • A Phase I clinical dose-finding study of DFP-14927 in patients with solid tumors has been completed at MD Anderson Cancer Center and the University of California, Los Angeles in the United States.
  • Subsequently, the concentration of DFP-10917, the active component of DFP-14927, delivering into cancer tissue in patients treated with DFP-14927 is being measured to confirm PK/PD relationship for the clinical efficacy of DFP-14927.
  • On 6th Feb. 2024, we are pleased to announce that we have submitted an abstract to the 2024 ASCO annual meeting to be held from May 31st this year in Chicago.

SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget

Retrieved on: 
Tuesday, February 6, 2024

The publication, entitled, “The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignancies”, is available online at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10732257/ .

Key Points: 
  • The publication, entitled, “The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignancies”, is available online at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10732257/ .
  • The research provides a robust pharmacodynamic and mechanistic foundation for the antiproliferative effects of SLS009 in hematologic cancers.
  • The research shows that through rapid CKD9 inhibition, SLS009 depletes the protective anti-apoptotic proteins produced downstream of CKD9.
  • The Company believes that this induced cancerous cell apoptosis is a key mechanism behind SLS009's robust anti-cancer activity.

PRISM MarketView Marks World Cancer Day

Retrieved on: 
Thursday, February 1, 2024

NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of unbiased market insight and company news, today recognizes the tremendous contributions of companies striving to develop treatments for cancer, a complex disease driven by numerous factors.

Key Points: 
  • NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of unbiased market insight and company news, today recognizes the tremendous contributions of companies striving to develop treatments for cancer, a complex disease driven by numerous factors.
  • To mark World Cancer Day , which will be held on February 4, PRISM MarketView highlights emerging companies working to improve the lives of cancer patients and their families by developing and commercializing innovative new treatments for cancer.
  • The company has entered a research agreement with the Johns Hopkins University School of Medicine for the development of Ivospemin.
  • Essa Pharma, a clinical stage pharmaceutical company, is focused on the development of small molecule drugs for the treatment of prostate cancer.